Candel Therapeutics (CADL) Common Equity (2020 - 2025)

Candel Therapeutics' Common Equity history runs 6 years deep, the most recent figure standing at $51.9 million for Q4 2025.

• In Q4 2025, Common Equity fell 21.72% year-over-year to $51.9 million; the TTM figure through Dec 2025 stood at $51.9 million (down 21.72% YoY), while the FY2025 annual figure was $51.9 million, down 21.72% from the prior year.
• Common Equity came in at $51.9 million for Q4 2025 at Candel Therapeutics, down from $80.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $90.2 million in Q2 2025 to a low of -$43.2 million in Q2 2021.
• A 5-year average of $36.5 million and a median of $49.8 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 249.85% in 2021 and surged 1148.95% in 2025, its largest moves.
• Candel Therapeutics' Common Equity stood at $64.1 million in 2021, then decreased by 25.61% to $47.7 million in 2022, then tumbled by 73.29% to $12.7 million in 2023, then jumped by 420.42% to $66.3 million in 2024, then decreased by 21.72% to $51.9 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $51.9 million, $80.1 million, and $90.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison